KEEPING YOU UP TO DATEClearstate Healthcare InsightsClearstate Insights is your single source to all our latest healthcare intelligence. From recently published reports offering thought-provoking analysis, to information about new products and services, we will ensure you are always kept informed. Sign up to Clearstate’s newsletter
China’s surgical advanced energy devices market outlook: wider VBP rollout and intensifying competition China’s advanced energy device market—covering… Healthcare | Asia | China Segmentation Surgical Devices Tracker | Surgical Gateway | The Gateway
China surgery: City and hospital trends Gain an understanding of where the opportunities and… Healthcare | Asia | China Segmentation Surgical Devices Tracker | Size and Share Segmentation | Surgical Gateway | Surgical Procedure Volume Segmentation | The Gateway
China’s general surgery device market: government regulates pricing Recovery in surgery volume is driving market growth for… Healthcare | Asia | China Segmentation Surgical Devices Tracker | Size and Share Segmentation | Surgical Procedure Volume Segmentation | The Gateway
Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge The impact of China’s latest covid-19 surge heads the… Healthcare | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx)
Outside of covid-19 diagnostics: Nine out of 16 APAC IVD markets have recovered to pre-pandemic levels Asia-Pacific (APAC) IVD markets have grown and exceeded… Healthcare | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | Infectious Diseases Testing Monitor | IVD Gateway | Molecular Diagnostics (MDx)
Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR Most-commonly tested cancer biomarkers using NGS in Europe… Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Larger gene panels are the predominant NGS testing strategy in EU5 Larger gene panels are the predominant NGS testing strategy… Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Europe: precision medicine and access to NGS cancer biomarker testing Precision medicine and access to NGS cancer biomarker… Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019 Proportion of cancer biomarker testing done with NGS… Healthcare | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Sequencing | Tissue Diagnostics (TDx)
Minimally invasive surgery device market in Latin America: four areas to watch The choice for traditional open surgery is becoming less… Healthcare | Americas | Minimally invasive surgery | Surgical Gateway
Insights into Europe’s covid-19 testing and technology use 2021-2022: PCR v serology v antigen Europe is shifting its covid-19-approach from pandemic to… Healthcare | Europe | IVD Gateway | Molecular Diagnostics (MDx)
The fastest-growing areas for LATAM’s next-generation sequencing market The next-generation sequencing (NGS) market is expected to… Healthcare | Americas | IVD Gateway | Sequencing
Sign up to our free newsletterThe latest trends and insights into the IVD and Surgical sectors, from our specialists and analysts, delivered directly to your inbox. Sign up to Clearstate’s newsletter today. Sign up now